IFNA2 and autoimmune polyendocrine syndrome type 1: Neutralisation of IFN-α evidently can occur in vivo during therapy with IFN-α2; some patients clearly become resistant because they make antibodies against it—usually with much lower titres/cross-reactivity than in APS1 [43,44].